Has Dhiren Shah, MD received payments from drug or device companies?

Yes. Drug and device makers reported $19,882 in general payments to Dhiren Shah, MD across 113 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dhiren Shah, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dhiren Shah, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dhiren Shah, MD

Radiation Oncology · Cheektowaga, NYNPI 1427011782

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (34.3%), ownership interests and speaking fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 61.3% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2020 at $5,527 and has fallen 94.0% since, to $331 in 2025. Among radiation oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,882in general payments, 2019–2025

Across 113 payments — averaging $175.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$12K
Novocure Inc.$5K
Johnson & Johnson$480
Siemens Medical Solutions USA, Inc.$430
AstraZeneca$154
Progenics Pharmaceuticals, Inc.$152
plus $1K from 21 others

What the payments were for

Speaking & faculty fees$4,00020%
Travel & lodging$7034%
Food & beverage$3,14416%
Gifts$170%
Ownership interest$5,19226%
Other$6,82734%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	6	$12,182
Novocure Inc.	18	$5,160
Johnson & Johnson	28	$480
Siemens Medical Solutions USA, Inc.	8	$430
AstraZeneca	8	$154
Progenics Pharmaceuticals, Inc.	3	$152
Varian Medical Systems, Inc.	3	$142
Blue Earth Diagnostics	5	$140
Myriad Genetic Laboratories, Inc.	6	$125
Sanofi	1	$100
Elekta, Inc.	1	$96
Reflexion Medical, Inc.	2	$84
Teleflex LLC	2	$79
Dendreon Pharmaceuticals LLC	4	$74
Genentech USA, Inc.	1	$74
Bayer	2	$70
Palette Life Sciences, Inc.	2	$62
Regeneron Healthcare Solutions, Inc.	2	$60
Tolmar Pharmaceuticals, Inc.	2	$39
Fortovia Therapeutics, Inc.	2	$35
Accuray Incorporated	1	$29
Daiichi Sankyo Inc.	1	$28
Nestle Healthcare Nutrition Inc.	1	$23
Telix Pharmaceuticals	1	$18
Medtec LLC	1	$17
Tactile Systems Technology Inc	1	$16
Ferring Pharmaceuticals Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,882 in reported general payments places this provider in the 90th percentile of 397 radiation oncology providers in New York.

See all radiation oncology providers in New York →

Medicare billing

Part B allowed, 2024

$860,660

Medicare patients

198

Services billed

4,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	78	$552
Procto-Med HcHydrocortisone	22	$345
Lidocaine Hcl ViscousLidocaine Hcl	14	$328
Ciprofloxacin Hcl	115	$102

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Cheektowaga

Chung ChungSyracuse$3.1M
Michael ZelefskyNew York$946K
Jeffrey BogartSyracuse$772K
Steven FinkelsteinSyracuse$578K
Shawn ZimbergPlainview$411K
Edward ObedianOyster Bay$391K
Nancy LeeNew York$233K
Dheerendra PrasadBuffalo$178K
Robert SamsteinNew York$125K
Jalal AhmedNew York$100K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →